Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2009
Event Date: July 8, 2009
Context: The company reported the entry into a material definitive agreement with Hadasit Medical Services and Development Ltd. ("Hadasit"), Prof. Itamar Raz, and Dr. Miriam Kidron. This "Third Agreement" covers consulting and clinical trial services.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial figures disclosed relate to the new agreement:
- Total Consideration: $400,000
- Previously Agreed Amount: $200,000 (under a March 8, 2006 agreement)
- Amount Paid to Date: $199,255
- Remaining Balance: $200,745
- Payment Terms: Ten equal quarterly installments commencing May 2009, contingent on study progress.
Material Changes and Related Party Transactions
The filing discloses a material related party transaction. Funds paid to Hadasit are deposited into a research fund managed by Dr. Miriam Kidron, who is identified as a director and officer of the Company. Under Hadasit's general policy, Dr. Kidron receives a management fee equal to 10% of all funds deposited into this research fund.
Guidance, Risks, and Unusual Items
Management Commentary: The agreement is intended to secure consulting and clinical trial services. Payment of the remaining balance is tied to the actual progress of the study.
Risks/Contingencies: The filing highlights a potential conflict of interest or related party risk due to the management fee structure benefiting a company director (Dr. Kidron). The full text of the agreement is incorporated by reference as Exhibit 10.1.
Investor Verification Checklist
- Review Exhibit 10.1 (Consulting Services Agreement) for detailed terms and conditions.
- Verify the status of the clinical study to assess the likelihood of future quarterly payments.
- Confirm the total value of the 10% management fee Dr. Kidron will receive from the $400,000 fund.
- Check subsequent filings for updates on the study progress and payment disbursements.